JP2024525222A5 - - Google Patents

Info

Publication number
JP2024525222A5
JP2024525222A5 JP2023579857A JP2023579857A JP2024525222A5 JP 2024525222 A5 JP2024525222 A5 JP 2024525222A5 JP 2023579857 A JP2023579857 A JP 2023579857A JP 2023579857 A JP2023579857 A JP 2023579857A JP 2024525222 A5 JP2024525222 A5 JP 2024525222A5
Authority
JP
Japan
Prior art keywords
cancer
use according
egfr
nsclc
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023579857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034702 external-priority patent/WO2022271935A1/en
Publication of JP2024525222A publication Critical patent/JP2024525222A/ja
Publication of JP2024525222A5 publication Critical patent/JP2024525222A5/ja
Pending legal-status Critical Current

Links

JP2023579857A 2021-06-24 2022-06-23 Ｅｒｋ１／２阻害剤併用療法 Pending JP2024525222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214764P 2021-06-24 2021-06-24
US63/214,764 2021-06-24
PCT/US2022/034702 WO2022271935A1 (en) 2021-06-24 2022-06-23 Erk1/2 inhibitor combination therapy

Publications (2)

Publication Number Publication Date
JP2024525222A JP2024525222A (ja) 2024-07-10
JP2024525222A5 true JP2024525222A5 (enExample) 2025-06-24

Family

ID=84544892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579857A Pending JP2024525222A (ja) 2021-06-24 2022-06-23 Ｅｒｋ１／２阻害剤併用療法

Country Status (8)

Country Link
US (1) US20240316046A1 (enExample)
EP (1) EP4358967A4 (enExample)
JP (1) JP2024525222A (enExample)
KR (1) KR20240055721A (enExample)
CN (1) CN117957001A (enExample)
AU (1) AU2022300355A1 (enExample)
CA (1) CA3223692A1 (enExample)
WO (1) WO2022271935A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017127282A1 (en) * 2016-01-19 2017-07-27 The General Hospital Corporation Cancer treatments and methods of selecting same
AU2019246719B2 (en) * 2018-03-30 2022-06-16 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and an Erk inhibitor
JP7234418B2 (ja) * 2019-05-16 2023-03-07 イーライ リリー アンド カンパニー Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ
US20230027072A1 (en) * 2019-10-28 2023-01-26 Asana Biosciences, Llc Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2

Similar Documents

Publication Publication Date Title
JP2024526155A5 (enExample)
EP4337191B1 (en) Egfr inhibitor for the treatment of head and neck cancer
JP2019532051A5 (enExample)
van der Kleij et al. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology: MBA van der Kleij et al.
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
Dziadziuszko et al. Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP)
Vasconcelos et al. EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors
LoConte et al. A multicenter phase 1 study of γ-secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors
Prelaj et al. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program
JPWO2023140329A5 (enExample)
Romano et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression
Giommoni et al. Results of the observational prospective RealFLOT study
US20240285625A1 (en) Erk1/2 and kras g12c inhibitors combination therapy
JP2024505680A5 (enExample)
Peng et al. Tinengotinib (TT-00420), a novel spectrum-selective small-molecule kinase inhibitor, is highly active against triple-negative breast cancer
Singh et al. RAS/RAF comutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer
CN117561062A (zh) 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法
Weng et al. Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients
JP2022514218A (ja) 血液に基づく腫瘍遺伝子変異量が、非小細胞肺がんの全生存期間の予測に役立つ
JP2024521696A5 (enExample)
Tissera et al. Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review
JP2024507221A5 (enExample)
Chic et al. Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non–Small-Cell Lung Cancer
Wong et al. Tivozanib for the treatment of metastatic renal cancer
Liu et al. Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report